GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio

DREAMM-8 results for Blenrep in multiple myeloma featured in a late-breaking presentation and ASCO's Press Programme


Updated results from a supported...

Related Keywords

China ,United Kingdom ,Macau ,United States ,Hong Kong ,Taiwan ,Japan ,Chicago ,Illinois ,Japanese ,Chinese ,American ,Hansoh Pharma ,Belantamab Mafodotin ,Drug Administration ,American Society Of Clinical Oncology ,Biowa Inc ,Kyowa Kirin Group ,Anaptysbio Inc ,European Commission ,Memorial Sloan Kettering Cancer Center ,Regulatory Agency ,Japanese Society Of Medical Oncology Annual Meetings ,Seagen Inc ,Ivy Brain Tumor Center ,Tesaro Inc ,Clinical Oncology ,Annual Meeting ,Memorial Sloan Kettering Cancer ,Medical Oncology Annual ,Ivy Brain Tumor ,Science Symposium ,Myelofibrosis Symptom Assessment Form ,Kyowa Kirin ,Great Britain ,Blenrep United Kingdom Summary ,About Jemperli ,Biologics License Application ,Breakthrough Therapy ,Priority Review ,Important Information ,